Literature DB >> 22870455

Opioids in chronic musculoskeletal conditions.

Jaime Calvo-Alén.   

Abstract

The use of opioids for benign disorders has been limited by concerns about these compounds' potential adverse events and their possible misuse. However, during the last few years an increased use in nonmalignant disorders, including rheumatologic diseases, has been observed. Herein, we review the scientific evidence for opioid therapy in three common scenarios in clinical rheumatology. Low back pain is a very frequent reason for consultation. Overall, the large majority of studies show a positive, yet rather moderate, effect of opioids in pain control, as well as in other outcomes including mood, work disability and anxiety. Similarly, opioids seem to have a role in the management of hip and knee osteoarthritis; indeed, they have been included in all international guidelines for the treatment of these conditions. However, clinical studies addressing opioid use in clinical situations are plagued by methodological limitations; furthermore, the large majority of these studies only provide short-term information about opiod utilization in these patients. Finally, opioids are currently being used as complementary therapy in inflammatory joint conditions whereby they may significantly improve the quality of life of some of these patients. Regarding their safety, severe adverse events, including abnormal drug-seeking behaviour, are very rare, but mild adverse events are frequent leading to drug discontinuation in a significant number of cases.

Entities:  

Keywords:  arthritis; low back pain; opioid; osteoarthritis

Year:  2010        PMID: 22870455      PMCID: PMC3383507          DOI: 10.1177/1759720X10370237

Source DB:  PubMed          Journal:  Ther Adv Musculoskelet Dis        ISSN: 1759-720X            Impact factor:   5.346


  45 in total

Review 1.  EULAR evidence based recommendations for the management of hip osteoarthritis: report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT).

Authors:  W Zhang; M Doherty; N Arden; B Bannwarth; J Bijlsma; K-P Gunther; H J Hauselmann; G Herrero-Beaumont; K Jordan; P Kaklamanis; B Leeb; M Lequesne; S Lohmander; B Mazieres; E Martin-Mola; K Pavelka; A Pendleton; L Punzi; B Swoboda; R Varatojo; G Verbruggen; I Zimmermann-Gorska; M Dougados
Journal:  Ann Rheum Dis       Date:  2004-10-07       Impact factor: 19.103

Review 2.  Systematic review: opioid treatment for chronic back pain: prevalence, efficacy, and association with addiction.

Authors:  Bridget A Martell; Patrick G O'Connor; Robert D Kerns; William C Becker; Knashawn H Morales; Thomas R Kosten; David A Fiellin
Journal:  Ann Intern Med       Date:  2007-01-16       Impact factor: 25.391

3.  Extended-release tramadol in the treatment of osteoarthritis: a multicenter, randomized, double-blind, placebo-controlled clinical trial.

Authors:  Theophilus J Gana; Maria Luz G Pascual; Rosa Rosanna B Fleming; Jeff R Schein; Carmela C Janagap; Jim Xiang; Gary J Vorsanger
Journal:  Curr Med Res Opin       Date:  2006-07       Impact factor: 2.580

4.  Psychomotor performance of patients with rheumatoid arthritis: cross-over comparison of dextropropoxyphene, dextropropoxyphene plus amitriptyline, indomethacin, and placebo.

Authors:  U Saarialho-Kere; H Julkunen; M J Mattila; T Seppälä
Journal:  Pharmacol Toxicol       Date:  1988-10

5.  Benefits of transdermal fentanyl in patients with rheumatoid arthritis or with osteoarthritis of the knee or hip: an open-label study to assess pain control.

Authors:  Karel Pavelka; Xavier Le Loet; Olav Bjorneboe; Gabriel Herrero-Beaumont; Ute Richarz
Journal:  Curr Med Res Opin       Date:  2004-12       Impact factor: 2.580

6.  Analgesic efficacy and safety of tramadol/ acetaminophen combination tablets (Ultracet) in treatment of chronic low back pain: a multicenter, outpatient, randomized, double blind, placebo controlled trial.

Authors:  Paul M Peloso; Luc Fortin; André Beaulieu; Marc Kamin; Norman Rosenthal
Journal:  J Rheumatol       Date:  2004-12       Impact factor: 4.666

Review 7.  OARSI recommendations for the management of hip and knee osteoarthritis, Part II: OARSI evidence-based, expert consensus guidelines.

Authors:  W Zhang; R W Moskowitz; G Nuki; S Abramson; R D Altman; N Arden; S Bierma-Zeinstra; K D Brandt; P Croft; M Doherty; M Dougados; M Hochberg; D J Hunter; K Kwoh; L S Lohmander; P Tugwell
Journal:  Osteoarthritis Cartilage       Date:  2008-02       Impact factor: 6.576

8.  Opioid therapy for chronic noncancer back pain. A randomized prospective study.

Authors:  R N Jamison; S A Raymond; E A Slawsby; S S Nedeljkovic; N P Katz
Journal:  Spine (Phila Pa 1976)       Date:  1998-12-01       Impact factor: 3.468

Review 9.  Efficacy and safety of opioids for osteoarthritis: a meta-analysis of randomized controlled trials.

Authors:  J Avouac; L Gossec; M Dougados
Journal:  Osteoarthritis Cartilage       Date:  2007-03-29       Impact factor: 6.576

10.  A comparison of the analgesic efficacy of Tramadol Contramid OAD versus placebo in patients with pain due to osteoarthritis.

Authors:  Francis Burch; Ritchard Fishman; Nicholas Messina; Bruce Corser; Florin Radulescu; Adrian Sarbu; Marcela M Craciun-Nicodin; Rodica Chiriac; André Beaulieu; Jude Rodrigues; Philippe Beignot-Devalmont; Alain Duplan; Sybil Robertson; Louise Fortier; Sylvie Bouchard
Journal:  J Pain Symptom Manage       Date:  2007-06-21       Impact factor: 3.612

View more
  2 in total

Review 1.  Characterizing the Interrelationships of Prescription Opioid and Benzodiazepine Drugs With Worker Health and Workplace Hazards.

Authors:  Michele Kowalski-McGraw; Judith Green-McKenzie; Sudha P Pandalai; Paul A Schulte
Journal:  J Occup Environ Med       Date:  2017-11       Impact factor: 2.162

2.  Predictors of long-term opioid use and opioid use disorder among construction workers: Analysis of claims data.

Authors:  Ann Marie Dale; Skye Buckner-Petty; Bradley A Evanoff; Brian F Gage
Journal:  Am J Ind Med       Date:  2020-11-24       Impact factor: 2.214

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.